Clinical Trial Update: MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MRD-guided maintenance therapy with gilteritinib versus sorafenib after allogeneic hematopoietic cell transplantation in FLT3-ITD-mutant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Nexavar (Sorafenib)
• Xospata (gilteritinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Status: RECRUITING